The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information:

Study Name on (link is external)
Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients
Study Drug Hypothiocyanite (OSCN-), bovine lactoferrin (bLF) and their combination (ALX-009)
Type of Study Drug Anti-infective
Study Title Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients
Study Phase 1
Study Sponsor Alaxia SAS

Link on (link is external)

Participating ECFS-CTN sites Please contact for most recent sitelist
Age 18 Years to 50 Years